title: Adult non Hodgkin's lymphoma patients: experience from a tertiary care cancer centre in north east India.
abstract: There is paucity of data on non Hodgkin's lymphoma (NHL) from our population in North-East India. In this retrospective study, patients were consecutively followed-up to see the clinic-pathological pattern of NHL, various responses, and pattern of relapses to first line treatment with chemotherapy. All patients in the present study received standard regimen of cyclophosphamde, doxorubicin, vincristine, prednisolone (CHOP) with or without rituximab (R-CHOP) as per our institutional protocol as first line therapy. Our study has shown that, in our adult population, the majority of NHL cases present with stage II and stage III disease and extra nodal involvement, B-cell lymphomas and diffuse large cell lymphomas being the most common subtypes. International prognostic index was a significant factor for varied responses to treatment. The majority of relapses after complete remission occurred in the first year.
authors: Department of Medical Oncology, Dr. B Borooah Cancer Institute, Guwahati, India E-mail : drmunlimahazarika@yahoo.com.
authors: Munlima
authors: M
authors: Hazarika
authors: Asif
authors: A
authors: Iqbal
authors: Manigreeva
authors: M
authors: Krishnatreya
authors: Jagannath Dev
authors: JD
authors: Sharma
authors: Chidananda
authors: C
authors: Bhuyan
authors: Bhargab Jyoti
authors: BJ
authors: Saikia
authors: Partha Sarathi
authors: PS
authors: Roy
authors: Rashmi
authors: R
authors: Das
authors: Pintu
authors: P
authors: Nandy
authors: Amal Chandra
authors: AC
authors: Kataki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007194:India; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D012074:Remission Induction / Q000379:methods; D012189:Retrospective Studies; D000069283:Rituximab / Q000008:administration & dosage; D063128:Tertiary Health Care; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone